Phospholipid for Liposome
Formulation
Transferrin Pre-Liposome
Numerous transporters are expressed on the surfaces of cancer cells; accordingly, with the use of liposomes chemically bound to, for example, transferrin, targeting of cancer cells might become feasible. Use of the lipid mixtures available from NOF, it would be possible to prepare liposomes possessing cancer-cell targeting ability at your own laboratories.
TF-01-PL is a specific lipid mixture containing phospholipids conjugated with phosphatidylcholine and transferrin.
If the directions in the instructions provided with your purchase are adopted, drug-containing liposomes with cancer-cell targeting ability can be prepared.
TF-01-PL is a specific lipid mixture containing phospholipids conjugated with phosphatidylcholine and transferrin.
If the directions in the instructions provided with your purchase are adopted, drug-containing liposomes with cancer-cell targeting ability can be prepared.
Transferrin-bound liposomes are directed toward the transferrin receptors
on the surface of cancer cells.
on the surface of cancer cells.
- Reagent for preparing transferrin-modified liposomes
- Addition of the drug solution
- Mixing and hydration of the drug with the reagent
- Preparation of the liposomes by size adjustment and sterilization
- Prolonged half-life of the drug in blood
- Avoidance of RES uptake
- Composed of highly purified starting materials, including high-purity phospholipids
- Ready for bulk supply
Specifications:
Content: Phosholipid, cholesterol, and transferrin
(Human Holo-transferrin)
Volume: Lipid: 20mg, Transferrin: 1mg per vial
Container: 10ml glass vial
Storage: Keep refrigerated
Reference:
1) Osamu lshida et al. (2001) Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with lntracellular Targeting Property to the Solid Tumors in vivo, Pharmaceutical Research, 18 (7).
2) Hisae Inuma et al. (2002) Intracelluar targeting therapy of cisplatinencapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer, Int. j. Cancer, 99, 130-137.
Content: Phosholipid, cholesterol, and transferrin
(Human Holo-transferrin)
Volume: Lipid: 20mg, Transferrin: 1mg per vial
Container: 10ml glass vial
Storage: Keep refrigerated
Reference:
1) Osamu lshida et al. (2001) Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with lntracellular Targeting Property to the Solid Tumors in vivo, Pharmaceutical Research, 18 (7).
2) Hisae Inuma et al. (2002) Intracelluar targeting therapy of cisplatinencapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer, Int. j. Cancer, 99, 130-137.
[How to prepare transferrin-modified drug-containing liposomes]
① Take TF-01-PL out of the refrigerator and let it warm to room temperature.
② Inject drug solution into the vial.
③ Gently shake the vial and mix the drug solution with the TF-01-PL powder to hydrate the powder.
④ Shake it gently every 5 minutes for 15 minutes (rolling shakers can also be used) so to ensure the formation of a homogeneous mixture.
② Inject drug solution into the vial.
③ Gently shake the vial and mix the drug solution with the TF-01-PL powder to hydrate the powder.
④ Shake it gently every 5 minutes for 15 minutes (rolling shakers can also be used) so to ensure the formation of a homogeneous mixture.
Note 1） The amount of drug solution:
This product contains 20 mg lipid in a vial. Addition of the drug solution to obtain a lipid of 1-2% is recommended (the amount of drug solution to be added is 1-2 ml). Be careful not to lose the amount of solution during the filtering process described below, since the amount of solution is very small.
Adding 1ml of purified water will make an approximately 30mM phosphate buffer. Adjust the drug solution buffer or salt concentration accordingly.
＜Syringe filtration＞
⑤ Suction the mixed solution prepared in④
⑥ Attach a disposable cellulose acetate filter (pore diameter:
0.22μm) to the syringe and filter the solution.
⑦ Transferrin-modified drug-containing liposomes (particle diameter: approximately 300nm) are obtained.
Note 2） Syringe filtration
This simple method can be employed to prepare liposomes when there are no specific requirements in terms of the liposome diameter or the amount of drug to be encapsulated in the liposomes. Aseptic injection directly into the vial after filtration will provide aseptic filtration at the same time. This product yields approximately 800μl of liposomes when 1ml of the drug solution is used and the solution is filtered with a 13-mm- diameter filter.
＜High-Pressure filtration＞
⑧ Put solution ④ into a pressure filtration system equipped with a polycarbonate filter.
⑨ Operate the pressure filtration system to filter the solution.
⑩ Transferrin-modified drug-containing liposomes are obtained. The particle diameter will be approximately 200 nm when a 0.2μm pore diameter filter is used. The drug-containing liposomes can be used after dilution or purification as needed.
Note 3）Refining the outer water phase
When the drug-containing liposomes are biologically evaluated, the drug in the outer water phase should be used after purification, according to the purpose of your research.
Purification in the outer water phase can be performed by conventional methods, such as ultrafiltration, dialysis, gel filtration and centrifugation.
Note 4）Concentration
Lipid concentration of 10mg/ml (1%) or less is recommended.
Note 5）High-Pressure filtration system
Contact us for further information and purchase.
This product contains 20 mg lipid in a vial. Addition of the drug solution to obtain a lipid of 1-2% is recommended (the amount of drug solution to be added is 1-2 ml). Be careful not to lose the amount of solution during the filtering process described below, since the amount of solution is very small.
Adding 1ml of purified water will make an approximately 30mM phosphate buffer. Adjust the drug solution buffer or salt concentration accordingly.
＜Syringe filtration＞
⑤ Suction the mixed solution prepared in④
⑥ Attach a disposable cellulose acetate filter (pore diameter:
0.22μm) to the syringe and filter the solution.
⑦ Transferrin-modified drug-containing liposomes (particle diameter: approximately 300nm) are obtained.
Note 2） Syringe filtration
This simple method can be employed to prepare liposomes when there are no specific requirements in terms of the liposome diameter or the amount of drug to be encapsulated in the liposomes. Aseptic injection directly into the vial after filtration will provide aseptic filtration at the same time. This product yields approximately 800μl of liposomes when 1ml of the drug solution is used and the solution is filtered with a 13-mm- diameter filter.
＜High-Pressure filtration＞
⑧ Put solution ④ into a pressure filtration system equipped with a polycarbonate filter.
⑨ Operate the pressure filtration system to filter the solution.
⑩ Transferrin-modified drug-containing liposomes are obtained. The particle diameter will be approximately 200 nm when a 0.2μm pore diameter filter is used. The drug-containing liposomes can be used after dilution or purification as needed.
Note 3）Refining the outer water phase
When the drug-containing liposomes are biologically evaluated, the drug in the outer water phase should be used after purification, according to the purpose of your research.
Purification in the outer water phase can be performed by conventional methods, such as ultrafiltration, dialysis, gel filtration and centrifugation.
Note 4）Concentration
Lipid concentration of 10mg/ml (1%) or less is recommended.
Note 5）High-Pressure filtration system
Contact us for further information and purchase.
   
|
|